- Earth Science Tech is a biotechnology company offering high-grade cannabinoids
- ETST has diverse subsidiaries that promote the company’s role as a leader in the CBD sector
- Earth Science Tech has various partnerships and distribution agreements in place
Earth Science Tech Inc. (OTCQB: ETST) operates in the hemp cannabinoid, nutraceutical, pharmaceutical and medical device research and development fields. A biotechnology company headquartered in Doral, Florida, ETST markets high purity and quality full-spectrum cannabinoids. The company’s wholly owned subsidiaries – including Earth Science Pharmaceutical Inc., Cannabis Therapeutics Inc. and Canna Inno Laboratories Inc. – concentrate on developing Earth Science Tech’s role as a worldwide leader in the CBD sector.
The company’s management team consists of experienced industry experts from the nutraceuticals, dietary supplement and life sciences fields. Earth Science Tech is developing new products and has secured several partnerships, with strategic plans to extend its footprint within the medical cannabis market. These partnerships will enable the company to develop new and novel cannabinoid-based pharmaceutical and nutraceutical products (http://nnw.fm/Jz5wk).
Wholly owned subsidiary Earth Science Pharmaceutical develops low-cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and diseases (STIs). The executive team of Earth Science Pharma has years of scientific, medical and business experience in the health, research and manufacturing fields. The subsidiary is working to develop and bring to market medical devices and vaccines that meet the specific needs of women.
Earth Science Pharma’s first medical device is MSN-2, a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. Earth Science Tech is advancing clinical testing of MSN-2 via a collaborative agreement with Laboratories BNK Canada (http://nnw.fm/vcA4o).
Wholly owned subsidiary Cannabis Therapeutics is working to take a leadership role in the development of new, cutting-edge, cannabinoid-based pharmaceutical and nutraceutical products. The company is invested in research and development to explore and harness the medicinal power of cannabidiol. Cannabis Therapeutics is also working to integrate the CBD molecule with existing generic drug molecules. The company’s mission is to help change the health care landscape by introducing its proprietary cannabis/cannabinoid-based products made for the global pharmaceutical and retail consumer markets.
Established in 2017, Canna Inno Laboratories is Earth Science Tech’s Canadian subsidiary, based in Montreal, Québec. The company’s mandate is to give ETST a foothold in Québec and provide the company with access to government grants offered to innovators in the pharmaceutical industry. One grant has been approved so far.
Earth Science Tech’s medical and industrial hemp products are made from high-grade, full-spectrum cannabinoids that are extracted using the supercritical CO2 liquid process. All of the company’s full-spectrum cannabinoids are mixed in coconut MCT oil to ensure the best delivery and absorption, and its offerings include CBD, CBDa, CBG, CBGa, CBN, CBC and CBDV; the cannabinoids also contain terpenoids, aminos, omegas, saponins and flavonoids.
Earth Science Tech has entered into agreements with CannaBiz and Desert Sun Distribution (http://nnw.fm/Q0zqC) for the distribution of the company’s high-grade, full-spectrum cannabinoids line throughout pharmacies, chiropractors, dispensaries, athletic clubs and clinics in the United States.
“We see tremendous synergy between our CBD line and the health care practitioner and pharmacy spaces,” ETST Chief Sales Officer David Barbash stated in a news release. “The distribution agreements with CannaBiz and Desert Sun Distribution, while important, are only a fraction of the opportunities we see for our CBD products.”
Earth Science Tech continues to develop its diverse portfolio and pipeline. The company offers investors the opportunity to be part of the burgeoning cannabinoid-based pharmaceutical and nutraceutical products market as it expands its role as a leader in different sectors. Earth Science Tech remains dedicated to developing leading-edge pharmaceutical and medical device offerings.
For more information, visit the company’s website at www.EarthScienceTech.com
NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at http://nnw.fm/ETST
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive instant SMS alerts, text STOCKS to 77948
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
No comments:
Post a Comment